First, although we included data from our center to validate the expression and prognostic value of ASF1B, our results present limited evidence about the mechanism by which ASF1B upregulation affects the outcome of patients and the TIME with HCC. This evidence concerns the gene ASF1B and hepatocellular carcinoma.